CL2012000738A1 - Compuestos heterociclicos derivados de indol, inhibidores de xantina-oxidasa; composición farmacéutica que los comprende; procedimiento de preparación; y uso en el tratamiento de enfermedades tales como hiperuricemia, gota, insuficiencia cardiaca, hipertensión, diabetes, hiperlipidemia, obesidad, aterosclerosis, entre otras. - Google Patents

Compuestos heterociclicos derivados de indol, inhibidores de xantina-oxidasa; composición farmacéutica que los comprende; procedimiento de preparación; y uso en el tratamiento de enfermedades tales como hiperuricemia, gota, insuficiencia cardiaca, hipertensión, diabetes, hiperlipidemia, obesidad, aterosclerosis, entre otras.

Info

Publication number
CL2012000738A1
CL2012000738A1 CL2012000738A CL2012000738A CL2012000738A1 CL 2012000738 A1 CL2012000738 A1 CL 2012000738A1 CL 2012000738 A CL2012000738 A CL 2012000738A CL 2012000738 A CL2012000738 A CL 2012000738A CL 2012000738 A1 CL2012000738 A1 CL 2012000738A1
Authority
CL
Chile
Prior art keywords
hyperuricemia
gout
hyperlipidemia
atherosclerosis
indole
Prior art date
Application number
CL2012000738A
Other languages
English (en)
Inventor
Jeaong Uk Song
Geum Tae Kim
Sung Pil Choi
Cheol Kyu Jung
Deaok Seong Park
Eun Sil Choi
Tae Hum Kim
Hyun Jung Park
Original Assignee
Lg Chemical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43857261&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012000738(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lg Chemical Ltd filed Critical Lg Chemical Ltd
Publication of CL2012000738A1 publication Critical patent/CL2012000738A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compuestos heterocíclicos derivados de indol, inhibidores dexantina-oxidasa; procedimiento de preparación; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades tales como hiperuricemia, gota, insuficiencia cardíaca, hipertensión, diabetes, hiperlipidemia, obesidad, aterosclerosis, entre otras.
CL2012000738A 2009-10-07 2012-03-23 Compuestos heterociclicos derivados de indol, inhibidores de xantina-oxidasa; composición farmacéutica que los comprende; procedimiento de preparación; y uso en el tratamiento de enfermedades tales como hiperuricemia, gota, insuficiencia cardiaca, hipertensión, diabetes, hiperlipidemia, obesidad, aterosclerosis, entre otras. CL2012000738A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20090095363 2009-10-07

Publications (1)

Publication Number Publication Date
CL2012000738A1 true CL2012000738A1 (es) 2012-09-14

Family

ID=43857261

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012000738A CL2012000738A1 (es) 2009-10-07 2012-03-23 Compuestos heterociclicos derivados de indol, inhibidores de xantina-oxidasa; composición farmacéutica que los comprende; procedimiento de preparación; y uso en el tratamiento de enfermedades tales como hiperuricemia, gota, insuficiencia cardiaca, hipertensión, diabetes, hiperlipidemia, obesidad, aterosclerosis, entre otras.

Country Status (26)

Country Link
US (1) US8729273B2 (es)
EP (1) EP2467378B1 (es)
JP (1) JP5702392B2 (es)
KR (1) KR101751325B1 (es)
CN (1) CN102574839B (es)
AP (1) AP3346A (es)
AR (1) AR078504A1 (es)
AU (1) AU2010304091B2 (es)
BR (1) BR112012007828B8 (es)
CA (1) CA2774133C (es)
CL (1) CL2012000738A1 (es)
CO (1) CO6430501A2 (es)
EA (1) EA021025B1 (es)
EC (1) ECSP12011793A (es)
ES (1) ES2599829T3 (es)
IL (1) IL218669A (es)
MA (1) MA33880B1 (es)
MX (1) MX2012003782A (es)
MY (1) MY162813A (es)
PE (1) PE20121088A1 (es)
SG (1) SG179186A1 (es)
TR (1) TR201203989T1 (es)
TW (1) TWI423962B (es)
UA (1) UA110197C2 (es)
WO (1) WO2011043568A2 (es)
ZA (1) ZA201202544B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI548630B (zh) * 2011-04-06 2016-09-11 Ｌｇ生命科學有限公司 １－（３－氰基－１－異丙基－吲哚－５－基）吡唑－４－羧酸結晶型及其製造方法
SI2750677T1 (sl) * 2011-08-30 2017-10-30 Chdi Foundation, Inc. Inhibitorji kinurenin-3-monooksigenaze, farmacevtski sestavki in postopki njihove uporabe
HRP20180644T1 (hr) 2013-03-29 2018-06-01 Teijin Pharma Limited Derivat pirazola
CN106715421A (zh) 2014-07-17 2017-05-24 Chdi基金会股份有限公司 用于治疗hiv相关病症的方法和组合物
CN104774172B (zh) * 2015-04-08 2017-03-22 河南师范大学 一种3‑氰基吲哚类化合物的合成方法
HUE052608T2 (hu) * 2015-09-02 2021-05-28 Sunshine Lake Pharma Co Ltd Karboxi-szubsztituált (hetero) aromás gyûrûs származékok, elõállítási eljárásaik és alkalmazásaik
CN106008488B (zh) * 2016-05-20 2018-10-30 广东东阳光药业有限公司 氰基吲哚类衍生物及其制备方法和用途
IL319473A (en) 2016-12-02 2025-05-01 Bioverativ Therapeutics Inc Methods for treating hemophilic arthritis using chimeric blood clotting factors
WO2018157801A1 (zh) * 2017-02-28 2018-09-07 广东东阳光药业有限公司 氰基取代的稠合双环衍生物及其制备方法和用途
BR112020022164A2 (pt) 2018-05-18 2021-02-02 Bioverativ Therapeutics Inc. métodos de tratamento de hemofilia a
BR112020022220A2 (pt) * 2018-06-01 2021-02-02 Autophagysciences Inc. novo composto e composição farmacêutica compreendendo o mesmo
CN111072647B (zh) * 2019-12-11 2021-02-26 沈阳药科大学 3-取代吲哚-5-氧代-4,5-二氢-1,2,4-噁二唑类化合物及其用途
CN111072634B (zh) * 2020-01-03 2022-07-22 中国医科大学 1-取代-3-取代-5-取代酰胺-1h-吲哚类化合物及其制备方法和应用
EP4218755A4 (en) * 2020-11-04 2024-03-27 Lg Chem, Ltd. METHOD FOR PRODUCING CRYSTALLINE PARTICLES OF 1-(3-CYANO-1-ISOPROPYL-INDOLE-5-YL)PYRAZOLE-4-CARBONIC ACID AND PHARMACEUTICAL COMPOSITION THEREFROM
CA3197405A1 (en) * 2020-12-01 2022-06-09 Lg Chem, Ltd. Stable oral formulation containing 1-(3-cyano-1-isopropyl-indol-5-yl) pyrazole-4-carboxylic acid
US20240173259A1 (en) * 2020-12-01 2024-05-30 Lg Chem, Ltd. Oral formulation comprising 1-(3-cyano-1-isopropyl-indole-5-yl)pyrazole-4-carboxylic acid and method for preparing same
CN112920170B (zh) * 2021-01-29 2023-06-20 中国医科大学 N-（吲哚-5-基）芳香杂环酰胺类化合物及其制备方法和用途
MX2023011500A (es) * 2021-04-16 2023-10-04 Lg Chemical Ltd Formulacion compuesta para administracion oral que comprende acido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxilico.
CN117255785A (zh) * 2021-04-27 2023-12-19 株式会社Lg化学 用于合成黄嘌呤氧化酶抑制剂的中间体的制备方法
US20240239768A1 (en) * 2021-04-27 2024-07-18 Lg Chem, Ltd. Method for preparing xanthine oxidase inhibitor
WO2022231261A1 (ko) * 2021-04-27 2022-11-03 주식회사 엘지화학 잔틴 옥시다아제 저해제 합성을 위한 중간체의 제조 방법
MX2023012844A (es) 2021-05-07 2023-12-06 Jiangsu Atom Bioscience And Pharmaceutical Co Ltd Un inhibidor de xantina oxidase.
TWI888729B (zh) * 2021-06-15 2025-07-01 南韓商Ｌｇ化學股份有限公司 包含１－（３－氰基－１－異丙基－吲哚－５－基）吡唑－４－甲酸之醫藥組成物
AR126164A1 (es) * 2021-06-17 2023-09-27 Lg Chemical Ltd Formulación compuesta para dosificación oral que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico
US20240317685A1 (en) 2021-07-02 2024-09-26 Lg Chem, Ltd. Method for preparing intermediate for synthesis of xanthine oxidase inhibitor
TWI822151B (zh) * 2021-07-02 2023-11-11 南韓商Ｌｇ化學股份有限公司 製備黃嘌呤氧化酶抑制劑的方法
JP2025515359A (ja) * 2022-04-27 2025-05-14 杭州新元素▲薬▼▲業▼有限公司 痛風に用いられる化合物
CN116715633B (zh) * 2022-04-27 2025-08-12 杭州新元素药业股份有限公司 可用于降尿酸的化合物
CN116283946B (zh) * 2023-03-27 2024-05-07 武汉工程大学 5-(n-取代吲哚-5-基)异噁唑-3-甲酸衍生物及其合成方法和应用
CN121419974A (zh) * 2023-07-10 2026-01-27 株式会社Lg化学 用于合成黄嘌呤氧化酶抑制剂的中间体的制备方法
CN118598859B (zh) * 2024-05-21 2025-08-19 武汉工程大学 一种含氮杂环吲哚类黄嘌呤氧化酶抑制剂及其制备方法和应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0513379T3 (da) 1990-11-30 1996-09-30 Teijin Ltd 2-Arylthiazolderivater og farmaceutisk præparat indeholdende sådanne
ID21775A (id) 1996-10-25 1999-07-22 Yoshitomi Pharmaceutical Senyawa-senyawa 1-fenilpirazol dan penggunaan farmasinya
JP2004502686A (ja) * 2000-06-30 2004-01-29 スージェン・インコーポレーテッド ４−ヘテロアリール−３−ヘテロアリーリデニル−２−インドリノンおよび蛋白質キナーゼ阻害剤としてのその使用
EP1299382B1 (en) * 2000-07-10 2005-09-21 Bristol-Myers Squibb Company Composition and antiviral activity of substituted indoleoxoacetic piperazine derivatives
WO2008011131A2 (en) * 2006-07-21 2008-01-24 Takeda Pharmaceutical Company Limited Amide compounds
DE10163991A1 (de) * 2001-12-24 2003-07-03 Merck Patent Gmbh Pyrrolo-pyrimidine
AU2003249535A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc 1,6-fused uracil derivatives as matrix metalloproteinase inhibitors
US20090149452A1 (en) 2005-07-01 2009-06-11 Nippon Chemiphar Co., Ltd. Xanthine oxidase inhibitor
CA2621038A1 (en) * 2005-10-07 2007-04-19 Astellas Pharma Inc. Triarylcarboxylic acid derivative
US8188113B2 (en) * 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
JP2008179621A (ja) * 2006-12-28 2008-08-07 Taisho Pharmaceutical Co Ltd 含窒素飽和複素環化合物
WO2008126770A1 (ja) 2007-04-05 2008-10-23 Astellas Pharma Inc. トリアリールカルボン酸誘導体の製造方法
US8003647B2 (en) 2007-04-11 2011-08-23 Kissei Pharmaceutical Co., Ltd. (Aza)indole derivative and use thereof for medical purposes
MX2009010491A (es) 2007-04-11 2009-11-09 Kissei Pharmaceutical Derivado heterociclico de 5 miembros y su uso para propositos medicos.
EP2338887A4 (en) 2008-10-15 2012-05-09 Kissei Pharmaceutical FUSIONED HETEROCYCLIC DERIVATIVE AND ITS USE FOR MEDICAL PURPOSES
WO2010045186A2 (en) 2008-10-16 2010-04-22 Automatic Bar Controls, Inc. Apparatus and method and turntable for on-demand distributing of a food product
US8785489B2 (en) * 2008-10-17 2014-07-22 Boehringer Ingelheim International Gmbh Heteroaryl substituted indole compounds useful as MMP-13 inhibitors
RU2012116207A (ru) * 2009-09-24 2013-10-27 Ф.Хоффманн-Ля Рош Аг Производные индола в качестве модуляторов crac

Also Published As

Publication number Publication date
CO6430501A2 (es) 2012-04-30
BR112012007828A2 (pt) 2016-03-08
MX2012003782A (es) 2012-08-31
BR112012007828B1 (pt) 2021-01-12
HK1170224A1 (zh) 2013-02-22
US8729273B2 (en) 2014-05-20
EP2467378A4 (en) 2013-04-24
JP2013507355A (ja) 2013-03-04
AR078504A1 (es) 2011-11-09
TW201118077A (en) 2011-06-01
SG179186A1 (en) 2012-05-30
WO2011043568A2 (en) 2011-04-14
MY162813A (en) 2017-07-31
EA021025B1 (ru) 2015-03-31
AU2010304091A1 (en) 2012-04-19
EP2467378B1 (en) 2016-07-27
TWI423962B (zh) 2014-01-21
AP2012006191A0 (en) 2012-04-30
EP2467378A2 (en) 2012-06-27
US20120184582A1 (en) 2012-07-19
UA110197C2 (ru) 2015-12-10
EA201270520A1 (ru) 2012-10-30
ZA201202544B (en) 2012-12-29
TR201203989T1 (tr) 2012-09-21
PE20121088A1 (es) 2012-08-17
CA2774133C (en) 2019-06-25
IL218669A (en) 2016-08-31
IL218669A0 (en) 2012-05-31
AU2010304091B2 (en) 2016-06-09
MA33880B1 (fr) 2013-01-02
WO2011043568A3 (en) 2011-09-29
KR101751325B1 (ko) 2017-06-27
ECSP12011793A (es) 2012-05-30
BR112012007828B8 (pt) 2021-05-25
CN102574839A (zh) 2012-07-11
KR20110037883A (ko) 2011-04-13
AP3346A (en) 2015-07-31
CA2774133A1 (en) 2011-04-14
CN102574839B (zh) 2015-11-25
ES2599829T3 (es) 2017-02-03
JP5702392B2 (ja) 2015-04-15

Similar Documents

Publication Publication Date Title
CL2012000738A1 (es) Compuestos heterociclicos derivados de indol, inhibidores de xantina-oxidasa; composición farmacéutica que los comprende; procedimiento de preparación; y uso en el tratamiento de enfermedades tales como hiperuricemia, gota, insuficiencia cardiaca, hipertensión, diabetes, hiperlipidemia, obesidad, aterosclerosis, entre otras.
CL2011000846A1 (es) Compuestos heterociclicos sustituidos; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c.
CL2013003598A1 (es) Compuestos derivados de benzooxazepinona, moduladores de canales de sodio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades seleccionadas de arritmias, insuficiencia cardiaca, angina, infarto al miocardio, diabetes, entre otras
CL2012002356A1 (es) Compuestos heterociclicos acidos derivados de ariltriazolonas ligadas a bisarilo, inhibidores de receptores de vasopresina v1a y v2; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar y/o prevenir insuficiencia cardiaca aguda y cronica, hiponatremia, entre otras.
CL2012003226A1 (es) Compuestos derivados de 5-fluoro-1h-pirazolopiridina ; procedimiento de preparacion de estos; composicion framaceutica que los comprende; y su uso en el tratamiento de enfermedades cardiovasculares, sexuales y metabolicas.
CL2008003116A1 (es) Compuestos heterocíclicos bicíclicos; composición farmacéutica que comprende a dichos compuestos; y su uso en el tratamiento o prevención de enfermedades tales como diabetes, obesidad, trastorno metabólico, enfermedad cardiovascular entre otras.
CL2008002916A1 (es) Compuestos derivados de triazolopiridina, inhibidores 11-beta-hidroxiesteroide deshidrogenasa tipo i; composicion farmaceutica que los comprende; y su uso en el tratamiento y/o prevencion de la diabetes, dislipidemia, obesidad, entre otros.
CL2008003847A1 (es) Compuestos derivados de 6-fenilpirazin-2-carboxamida y 6-fenilpirazin-2-carbotioamida, inhibidores de dgat-1; composicion farmaceutica; y su uso en el tratamiento de la diabetes mellitus y obesidad.
ECSP078013A (es) Inhibidores heterocíclicos de mek y métodos de uso de ellos
CL2011001497A1 (es) Compuestos derivados de heterociclos, modulador de gpr120; composicion farmaceutica; y su uso para el tratamiento de diabetes tipo i,ii y sindrome metabolico.
CL2012000937A1 (es) Compuestos heterociclicos espiro derivados de ciclohexano, inhibidores de hsl; procedimiento de preparacion; composicion farmaceutica que los comprende; uso del compuesto para el tratamiento de diabetes, sindrome metabolico, dislipidemia, aterosclerosis u obesidad.
EA201170151A1 (ru) Пиперидиниловые агонисты gpcr
CL2012003026A1 (es) Composicion farmaceutica que comprende pioglitazona y linagliptina; procedimiento de preparacion; uso en el tratamiento de la diabetes tipo 2 o la obesidad.
CL2007002492A1 (es) Compuestos derivados de bi-,tri o policiclos no aromaticos, inhibidores de la enzima 11-beta-hidroxiesteroide deshidrogenasa tipo i; proceso de preparacion de estos; composicion famaceutica que los comprende; uso en el tratamiento de enfermedades tales como la obesidad, diabetes y dislipidemia, entre otras.
EA201171081A1 (ru) Производные индола в качестве антагонистов рецептора crth2
CL2011000087A1 (es) Compuestos derivados de heteroarilo sustituido, inhibidores de los receptores dgat1; composicion farmaceutica; y su uso para tratar la diabetes tipo ll y obesidad.
CL2009000889A1 (es) Compuestos derivados de 2-oxo-2,5-dihidro pirrol propionamida, activadores de glucoquinasa; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compestos; y su uso en el tratamiento de diabetes mellitus.
CL2012002250A1 (es) Compuestos heterociclicos fusionados derivados de pirimidinonas, inhibidores potentes de cdc7; composicion farmaceutica; y su uso en la prevencion o el tratamiento del cancer.
CL2011003350A1 (es) Compuestos derivados de heterociclo nitrogenados, moduladores pkm2; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer.
CL2008002871A1 (es) Compuestos derivados de oxadiazol-bencimidazol; composicion farmaceutica que los contiene y su uso como inhibidores de dgt1 para el tratamiento de la tolerancia deteriorada a la glucosa, diabetes tipo 2 y obesidad.
GT200800250A (es) Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina
CL2011002182A1 (es) Compuestos heterociclicos que contienen 2 o mas heterociclos con n como heteroatomos del ciclo, agonistas de gpr119 e inhibidores de dpp-iv; composicion farmaceutica; y su uso en el tratamiento de la diabetes tipo ii, obesidad, sindrome metabolico, tolerancia deteriorada a la glucosa e hiperlipidemia, entre otras enfermedades..
CL2008001994A1 (es) Compuestos derivados de pirazin-2-ona; combinacion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, aterosclerosis, hipertension, entre otras.
CL2012001298A1 (es) Compuestos derivados del acido carbomoil-metilamino acetico sustituido, inhibidores de nep; composicion farmaceutica; combinacion farmaceutica; y uso para el tratamiento de hipertension arterial, hipertension pulmonar, insuficiencia cardiaca, entre otras.
CL2011003160A1 (es) Compuestos derivados de heterociclicos, moduladores cb2; composicion farmaceutica que los comprende; y uso en el tratamiento de enfermedades reumaticas, autoinmune, inflamatorias, dolor, entre otras.